NZ210618A - Oral composition for inhibiting dental plaque and gingivitis - Google Patents

Oral composition for inhibiting dental plaque and gingivitis

Info

Publication number
NZ210618A
NZ210618A NZ210618A NZ21061884A NZ210618A NZ 210618 A NZ210618 A NZ 210618A NZ 210618 A NZ210618 A NZ 210618A NZ 21061884 A NZ21061884 A NZ 21061884A NZ 210618 A NZ210618 A NZ 210618A
Authority
NZ
New Zealand
Prior art keywords
gingivitis
oral
weight
composition according
salt
Prior art date
Application number
NZ210618A
Inventor
A Gaffar
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Publication of NZ210618A publication Critical patent/NZ210618A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005Antimicrobial preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Description

<div class="application article clearfix" id="description"> <p class="printTableText" lang="en">New Zealand Paient Spedficaiion for Paient Number £10618 <br><br> 210618 <br><br> Priority Date(s): .??.&amp; .. <br><br> Complete Specification Filed: Cless: .. Kl/tks ftmzi/gc?. <br><br> Publication Date: ... 3. .P.^IAT <br><br> P.O. J., •rrsl, No: / <br><br> NO DRAWINGS <br><br> i 1 ^ J :^4 <br><br> Patents Form No. S Number <br><br> PATENTS ACT 1953 Dated <br><br> COMPLETE SPECIFICATION ANTIPLAQUE/ANTIGINGIVITIS METHOD <br><br> S/We COLGATE-PALMOLIVE COMPANY a corporation organised under the laws of the State of Delaware, United States of America, of 300 Park Avenue, New York, New York 10022, United States of America do hereby declare the invention for which we pray that a Patent may be granted to jne/us. and the method by which it is to be performed, to be particularly described in and by the following statement: <br><br> • I ■ (followed by page 1a) <br><br> I ' <br><br> * 21061 <br><br> ThiB invention relates to the use of non-anclbacterial j agents and oral compositions for promoting human oral hygiene, and especially to a method for treating, controlling or inhibiting both plaque and gingivitis, which latter is characterized by such symptoms a6 inflammation, bleeding, recession, and/or swelling of the gums. Types of gingivitis Include afunctional gingivitis, gingivitis marginal and cotton-roll gingivitis. <br><br> Gingivitis leads to periodontitis. <br><br> The gums are seriously harmed by deposits of dental !! plaque, a combination of minerals and bacteria found in the mouth. |j The bacteria associated with plaque can secrete enzymes and j! endotoxins vhich can irritate the gums and cause ah Inflammatory t <br><br> gingivitis. As the gums become increasingly irritated by this process they have a tendency to bleed, lose their toughness and resiliency, and separate from the teeth, leaving periodontal j pockets in which debris, secretions, more bacteria and tuxins j <br><br> I <br><br> further accumulate. It is also possible for food to accumulate in these pockets, thereby providing nourishment for increased growth of bacteria and production of endotoxins and destructive enzymes. <br><br> Actinomyces vlscosus, a gram positive rod, has been identified as implicated in the etiology of gingivitis Loeche et al "Bacteriology of human experimental gingivitis: effects of plaque and gingivitis sores," Infection and Immunity 2_1^, 830-839 (1978). This organism attaches to tooth surfaces to form the dental plaque. <br><br> A multitude of materials have been previously proposed and employed for controlling plaque and gingivitis, but none have been entirely satisfactory. For example, some of such materials <br><br> -la- <br><br> 210 6 18 <br><br> . ! <br><br> ( <br><br> have been found to be unstable In the presence of the anionic surface active agents generally present in conventional .oral preparations. A number of such materials such as the catlonlc quaternary ammonium agents exert an antibacterial function which undesirably tends to disrupt or destroy the normal microflora of the mouth and/or the digestive system. <br><br> U.S. 3,429,963 issued February 25, 1969 to Leo Shedlovsky and assignee in common with the instant application proposes, <br><br> among a number of other water soluble polyelectrolytes, the use of polyvinyl phosphonic acid (VPA polymer) or salts thereof for complexlng calcium and Inhibiting oral calculus* but the sole in vivo test described therein involved the supplying of drinking water containing a hydrolyzed copolymer of ethylene and maleic anhydride for ad libitum drinking by rats for a period of five days. This test is in the nature of a stoichiometric complexation, <br><br> I <br><br> of calcium and is unrelated to the threshhold effect occurring ; in actual oral use involving treatment of dental surfaces 1 to 3 ! <br><br> I <br><br> times substantially daily for at least 2 weeks or lifetime. When subjected to such an actual use test, polyvinyl phosphonic acid failed to significantly inhibit oral calculus. <br><br> U.S. 4,342,857 issued August 3, 1982 to Abdul Gaffar, applicant herein, discloses and claims antiglnglvltis compositions containing a vinyl phosphonic acid/vinyl phosphonyl fluoride copolymer, but a number of scientists, authorities and/or juris-dictions object to administration of fluorinated materials to . <br><br> humans. ' <br><br> » <br><br> It is an object of this invention to provide an antiplaquej' antiglnglvltis method which will not be subject to one or more ; <br><br> of the above deficiencies and objections. Other objects and advantages will appear as the description proceeds. <br><br> 2- <br><br> i <br><br> 210818 <br><br> The attainment of the above objects is made possible by my discovery that VPA polymer and its salts interfere with or inhibit the attachment of Actinomyces vIscqbus to saliva coated hydroxyapatl te (1IAP) beads. This is a reliable Indication that the agent would Interfere with the attachment of the organism to tooth surfaces, should reduce plaque, and hence reduce or inhibit gingivitis. Such antiglnglvltis'activity has in fact been corroborated by an in vivo test on beagles as more fully discussed belov. <br><br> This invention accordingly includes a method, of inhibiting human dental plaque and gingivitis comprising applying .to the human oral cavity a composition containing a dentally acceptable oral vehicle and an effective plaque- and gingivitis- inhibiting amount of polyvinyl phosphonic acid or an orally acceptable salt thereof. <br><br> The VPA polymer of this invention should preferably have a number average molecular weight (obtained from viscosity or light scattering measurements) of about 6,000 to about 8,000 find may be pre-, pared in known manner by polymerizinq vinyl phosphonyl dichloride under substantially anhydrous conditions in the presence of a free radical catalyst, and then mixing the resulting polymer with water to hydrolytically convert the vinyl phosphonyl dichloride units in the polymer to VPA units. The resulting polymer is in free acid form and may desirably be converted to salt form by treatment with any orally acceptable cation - providing ba$e such as alkali metal (e.g. sodium or potassium), ammonium, ^1-18 <br><br> mono-, di- and tri-substituted ammonium, (e.g. alkanol substituted ammonium, such as mono-, di-.aud t r 1 -o t lia no lummon i tun , organic amines, etc. - <br><br> -3- <br><br> Ai'S <br><br> \ <br><br> It will be understood that the mono- and di- salt forms of the polymer are the equivalent of the free acid form and that the term "water soluble" applicable to all such forms is inclusive of readily water dispersible forms thereof in the usual use concentrations . <br><br> It will also be understood that the VPA polymer may also contain minor proportions, i.e. less than 50 wt. %, preferably less than about 10 wt. %, more preferably less than about 5 wt. % most preferably less than about 2 wt. %, of units derived from other non-fluorinated ethylenically unsaturated monomers which, in type and amount, are nontoxic and do not interfere with the desired water soluble and antigingivitis activities of the polymer. Other such monomers may, for example, include olefins such as ethylene, propylene, isopropylene, butylene and isobutylene, vinyl lower alkyl'ethers such as vinyl methyl, ethyl and isobutyl ethers, alpha, beta unsaturated carboxylic acids and their lower alkyl and substituted lower alkyl esters such as acrylic, methacrylic, aconitic, maleic and fumaric acids and their methyl, ethyl, isobutyl and dimethylaminoethyl esters, allyl alcohol and acetate, vinyl and vinylidene halides, vinyl lower alkanoic acid esters such as vinyl acetate and butyrate, acrylamide and methacrylamide and N-lower alkyl and N,N-dilower alkyl substituted derivatives thereof, and the like. <br><br> The concentration of the VPA polymeric antigingivitis agent in oral compositions can range widely, typically upwards of about 0.01% by weight with no upper limit except as dictated by cost or incompatibility with the vehicle." Generally, concentrations of about 0.01% to about 10.0%, preferably about 0.1% to about 8.0%, more preferably about 0.5% to about 5.0% by weight aie utilized. Oral compositions which in the ordinary course of usage could be accidentally ingested preferably contain concentrations in the lower portions of the foregoing ranges. <br><br> • J <br><br> 2 10 61S, <br><br> In certain highly preferred forms of the Invention, the oral composition may be substantially liquid such as mouthwash or rinse. Such preparations generally contain a humectant and the vehicle is typically a water-alcohol mixture. Generally, the ratio of water to alcohol is in the range of from about 1:1 to about 20:1 preferably from 3:1 to 20:1 and most preferably about 17:3, by weight. The total amount of water-alcohol mixture in this type of preparation is typically in the range' of from about 70 to about 99.9Z by weight of the preparation. The pH of such liquid and other preparations of the invention is generally in the range of from about 4.5 to about 9 and typically from about 5.5 to 8. The pH is preferably in the range of from about 6 to about 8.0. It is noteworthy that the compositions of the invention may be applied orally at a lower pH without substantially decalcifying dental enamel. <br><br> Such liquid oral preparations may also contain a surface active agent and/or a fluorine-providing compound. <br><br> In certain other desirable forms of this invention, the oral composition .may be substantially solid or pasty in character such as toothpowder, a dental tablet, a toothpaste or dental cream. The vehicle of such solid or pasty oral preparations contains polishing material. Examples of polishing materials are water-insoluble sodium metaphosphate, potassium metaphosphate tricalcium phosphate, calcium pyrophosphate, magnesium ortho-phosphate, trimagnesiuin phosphate, calcium carbonate, alumina, j i <br><br> hydrated alumina, aluminum silicate, zirconium silicates, ! <br><br> silica, bentonite, and mixtures thereof. Preferred polishing j materials include crystalline silica having particle sizes of j j <br><br> up to 5 microns a mean particle size of up to 1.1 microns, and ! <br><br> t a surface area of up to 50,000 cm^/gm«» silica gel, complcx j amorphous alkali metal alum1nosi1icate, hydrated uluminn, | <br><br> i dicalciura phosphate. '&gt; <br><br> -5- <br><br> Alumina, particularly che hydrated alumina sold by Alcoa as C333, which has an alumina content of 64.92 by weight, a silica content of 0.0082, a ferric oxide content of 0.0032, and a moisture content of 0.0372, at 110°C., and which has a specific gravity of 2.42 and a particle size such that 1002 of the particles are less than 50 microns and 842 of the particles are less than 20 microns, is particularly desirable. <br><br> When visually clear gels are employed, a polishing agent of colloidal silica, such as those sold under the trademark SYLOID as Syloid 72 and Sylold 74 or under the trademark SANTOCEL aB Santocel 100 and alkali metal aluminosilicate complexes are particularly useful, since they have refractive indices close to the refractive indices of gelling agent-liquid (including water and/or humectant) systems commonly used in dentifric-es. <br><br> Many of the so-called "insoluble" polishing materials are anionic in character and also include small amounts of soluble material. Thus, insoluble sodium metaphosphate may be formed in any suitable manner, as illustrated by Thorpe's Dictionary of Applied Chemistry, Volume 9, fourth Edition, pp. 510-511. The forms of insoluble - sodium metaphosphate known as Madrell's salt and Kurrol's salt are further examples of suitable materials. <br><br> These metaphosphate salts exhibit a minute solubility in water, and therefore are commonly referred to as insoluble metaphosphates There is present therein a minor amount of soluble phosphate material as impurities, usually a few percent such as up to 42 by weight. The amount of soluble phosphate material, which is believed to include a soluble sodium trimetaphosphate in the case of insoluble metaphosphate, may be reduced by washing with water if desired. The insoluble alkali metal metaphosphate is typically employed in powder form of a particle size such that no more than about 12 of the material is larger than 37 microns. <br><br> -6- <br><br> I <br><br> The polishing material is generally present in amounts ranging from about 10 to about 992 by weight of the oral preparation. Preferably, it Is present in amounts ranging from about 10 to about 752 in toothpaste, and from about 70 to about 992 in toothpowder. <br><br> In the preparation of toothpowders, it is usually sufficient to admix mechanically, e.g., by milling, the various solid ingredients in appropriate quantities and particle sizes. <br><br> In pasty oral preparations the above-defined combination of the antigl/nglvltis agent and polishing material should be compatible with the other components of the preparation. Thus, in a toothpaste, the liquid vehicle may comprise water and humectant typically in an amount ranging from about 10 to about 902 by weight of the preparation. Glycerine, sorbitol, or poly- <br><br> i ethylene glycol may also be present as humectants or binders. Particularly advantageous liquid ingredients are polyethylene glycol and polypropylene glycol. Also advantageous are liquid mixtures of water, glycerine and sorbitol. <br><br> In clear gels where the refractive index is an important consideration, about 3-302 by weight of water, 0 to about 802 by weight of glycerine, and about 20-282 by weight of sorbitol is preferably employed. A gelling agent, such as natural or synthetic gums or gumlike materials, typically Irish moss, sodium carboxy-methylcellulose, methyl cellulose, hydroxyethyl cellulose, gum tragacanth, polyvinylpyrrolidone, starch, and preferably hydroxy-propyl methyl cellulose and the Carbopols (e.g. 934,940 and 941), etcetera is usually present in toothpaste in an amount of up to about 102 by weight, preferably in the range of from about 0.5 to about 52. In a toothpaste or gel, the liquids and solids are proportioned to form a creamy or gelled mass which is extrudable from a pressurized container or from n collapsible, e.g., aluminum or lead , tube. <br><br> 210 <br><br> The solid or pasty oral preparation which typically has a pU measured on a 20Z slurry of about 4.5 to 9, generally about 5.5 to about 8 and preferably about 6 to about 8.0 may also contain a surface active agent and/or a fluorine-providing compound . <br><br> It will be understood that, as is conventional, the oral preparations are to be sold or otherwise distributed, in suitable labelled packages. Thus a jar of mouthrinse will have a label describing it, in substance, as a mouthrinse or mouthwash and having directions for its use; and a toothpaste will usually be in a collapsible tube, typically aluminum or lined lead, or other squeeze dispenser for metering out the contents, having a label describing it, in substance, as a toothpaste or dental cream. <br><br> The oral compositions of this invention may contain a non-soap synthetic sufficiently water soluble organic anionic or nonlonlc surfactant in concentrations generally ranging from about 0.05 to about 10, preferably about 0.5 to about 5, weight percent, to promote wetting, detersive and foaming properties. U.S. Patent No. 4,041,149 discloses such suitable anionic surfactants in column 4, lines 31-38, and such suitable nonlonic surfactants in column 8, lines 30-68 and column 9, lines 1-12 which passages are incorporated herein by reference thereto. <br><br> In certain forms of this invention a fluorine-providing compound is present in the oral preparation. These compounds may be slightly soluble in water or may be fully water-soluble. They are characterized by their ability to release fluoride ions in water and by substantial freedom'from reaction with other components of the oral preparation. Among these materials are inorganic fluoride salts, such as soluble alkali metal, alkaline earth metal and heavy metal salts, for example, sodium fluoride, potassium fluoride, ammonium fluoride', Ca fluoride, a copper <br><br> 2 ? 0 ' ' <br><br> fluoride such as cuprous fluoride, zi.nc fluoride, a tin fluoride such as stannic -fluoride or stannous chlorofluoride, barium fluoride, sodium fluorsllicate, ammonium fluorosilicate, sodium fluorozirconate, sodium monofluorophosphate, aluminum mono- and di-fluorophosphate, and fluorinated sodium calcium pyrophosphate. Alkali metal and tin fluorides, such .as sodium and stannous fluorides, sodium monofluorophosphate and mixtures thereof, are preferred. <br><br> The amount of the fluorine-providing compound is dependent to some extent upon the type of compound, its solubility and the type of oral preparation, but it must be a nontoxic amount. In a solid oral preparation, such as toothpaste or toothpowder, an amount of such compound which releases a maximum of about IZ by weight of the preparation is considered satisfactory. Any suitable minimum amount of such compound may be used, but it is preferable to employ sufficient compound to release about 0.005 to IX, and preferably about 0.1% of fluoride ion. Typically, in the cases of alkali metal fluorides and stannous fluoride, this component is present in an amount up to about 2% by weight, based on the weight of the preparation, and preferably in the range of about 0.05 to IX. In the case of sodium mono-fluorophosphate, the compound may be present in an amount up to 7.6% by weight, more typically about 0.76%. <br><br> In a liquid oral preparation such as a mouthwash, the fluorine-providing compound is typically present in an amount sufficient to release up to about 0.13%, preferably about 0.0013 to 0.1% and most preferably about 0.0013% by weight, of fluoride. <br><br> Various other materials may be incorporated in the oral preparations of this invention, subject to the above. Examples are whitening agents, preservatives, silicones, chlorophyll compounds, and ammoniated material such as urea, diammonium <br><br> -9- <br><br> phosphate, and mixtures thereof. These adjuvants, where present, are lrtco r.po r a ted in the preparations in amounts which do not substantially adversely affect the properties and characteristics desired. * <br><br> Any suitable flavoring or sweetening material may also be employed, also subject to the above. Examples of suitable flavoring constituents are flavoring oils, e.g., oils of spearmint, peppermint, wintergreen, sassafrass, clove, sage, eucalyptus <br><br> Jmajoram, cinnamon, lemon and orange, and methyl salicylate. <br><br> &gt; <br><br> Suitable sweetening agents include sucrose, lactose, maltose, sorbitol, sodium cyclamate, perillartine, APM (aspartylphenyl-alanine, methyl ester) and saccharin. Suitably, flavor and sweetening agents may together comprise from about 0.1 to 5Z or more of the preparation. <br><br> In the practice of this invention an oral composition according to this invention such as a mouthwash or toothpaste containing the antigingivitis agent in an orally acceptable vehicle may be prepared by unifying the components in conventional manner, and applied to the gingiva and teeth regularly, substantially daily, e.g. from about 1 to 3 times daily or every second or third day, etc., at a pH of about 4.5 to about 9, generally about 5.5 to about 8.5, preferably about 6 to about 8, . preferably for at least two weeks up to eight weeks or more or lifetime. <br><br> In the case of chewing gum and other products, the VPA active ingredients can be incorporated in any suitable manner during the usual manufacture of the product. For example, they can be incorporated in a warm gum base with stirring to distribute the same uniformly therein. They can also be added to the exterior or outer surfaces of a gum base in order to coat the base. The usual gum boaC9 can be used, rcprusuntjitlvo materials being jelutone, rubber latex, vinylite resins, etc., in addition <br><br> -10- <br><br> -1 210618 <br><br> to other usual materials such as plasticizers or softeners, sugar'or .other suitable carbohydrates such as glucose, sorbitol, etc . <br><br> The following examples are further illustrative of the nature of this Invention but it is understood that the Invention is not limited thereto. All amounts and proportions referred to herein and in the appended claims are by weight, and temperatures are In degrees C unless otherwise indicated. The VPA polymer employed in these examples was in the form of the disodium salt. <br><br> •rsMr <br><br> A <br><br> o'' <br><br> 0APR W88 f <br><br> .... ^ 'vV <br><br> C E o <br><br> -It" <br><br> 2106' <br><br> EXAMPLE I <br><br> Adsorption' of Sodium Polyvinyl Phosphonate to Dental Enamel: <br><br> The adsorption of the polymer to enamel surfaces was measured In vitro. Human extracted, non-carious and non-filled molar teeth were cleaned by pumicing. They were then polished with a rubber cup and polishing agent. They were mounted onto a rubber stopper via a nichrome wire which was tied through a hole In the roots. A sodium salt of polymer solutions at pH 7.0 were dispensed in polyethylene tubes. The teeth were submerged In the solution at 37°C. for 1 hour under a continuous agitation. Special care was taken to avoid the contact of solution with roots of the teeth. After one hour incubation, the teeth were removed and the solutions were analyzed for the amount of polymer left in the solution. The adsorption was calculated by a difference between amount initially added minus the amount left after exposing to teeth. <br><br> The concentration of the polymer in the solution was assessed by turbidimetric measurements using 5M CaCl2 solution at pH 4.5. 1 cc. of CaCl2 was added to 1 cc. of the polymer solution. The turbidity of resulting colloidal suspension at 500 nanometer proved to be proportional to the polymer concentration ranging from 1 to 8 mgs/ml. A calibration curve was carried out with the known amount of the polymer. <br><br> TABLE 1 <br><br> Results: <br><br> Cone, of POly- Ant. Left After Tooth Amt. Adsorbed to <br><br> N^2^PA (rag/ml) Immersion (mg/ml) Teeth (mg/ml) <br><br> 2 0.4 1.6 <br><br> 3 0.7 2.3 <br><br> 4 1.1 2.9 <br><br> 5 1.6 3.4 <br><br> 6 2.4 3.6 <br><br> 7 3.3 3.7 <br><br> The data indicated a significant adsorption of the VPA polymer to enamel surfaces. <br><br> -12- <br><br> i <br><br> EXAMPLE II <br><br> Effcct of Polymer on the Adsorption of Actinomyces Vlscosus T14 on Saliva Coated Hydroxyapatltc (HAP) lit?ads : <br><br> 80 mgs. of HAP beads were pre-coatcd with human saliva (blood type A) for 12 hours. The beads were washed and pre-treated with the solution of the polymer at pH 7.0 for 5 minutes. The treated beads were washed with a buffer consisting of 0.05 M KC1 1 mM P04, ImM CaCl2 and 0.1 mM MgCl2 at pH 6.0. This buffer simulates saliva inorganic constituents. <br><br> For the adsorption studies the mixture (1.0 ml) contained 5 x 10^ ^H thymidine labelled bacteria (Ac t inomyces viscosus). 30 mg saliva coated beads (S HAP) and the buffer. The mixture was continuously shaken at room temperature for 2 hours. The beads were allowed to settle for one minute and the supernatant which contained unadsorbed cells was removed. The radioactivity was measured via liquid scintillation counts. Portions of known labelled cells were counted in a similar manner so that counts per minute may be related to bacterial cell member. Control bacterial suspensions were incubated with S-1IAP beads. <br><br> TABLE II <br><br> Result s: <br><br> Effects of Pre-Treating Saliva Coated HAP Beads With Polyvinyl Phosphonate on Adsorption of Bacteria <br><br> A. Viscosus LY7 <br><br> S-HAP Cells Adsorbed (X 10^) <br><br> Treatment per 20 mg S-HAP Z Relative to Buffer <br><br> Buffered KC1 3.88 + 0.04 100 <br><br> IZ Na2VPA 1.23 ± 0.05 32 Polymer <br><br> 0.1% Na2VPA 3.54 t 0.16 91 Pclymer <br><br> 0.01Z Na2 VPA 3.55 t 0.09 92 <br><br> -13- <br><br> 2 <br><br> The resulca show that a pre-trcatmcnt of S-llAP with IZ polyvinyl pliosphonatc was significantly effective in inhibiting bacterial a t tachment. <br><br> EXAMPLE HI <br><br> This study in 20 beagle dogs evaluated the effect of a placebo and a rinse containing IX sodium salt of polyvinyl phosphonic acid on plaque/gingivitis for 4 weeks. The dogs were given complete prophylaxis to remove soft and hard dental deposits. A disclosing solution vaa used co insure the complete removal of dental deposits. The beagles were kept on a so'ft diet for 4 weeks. Group I (10 dogs) were then treated with the placebo rinse, while Group II was treated with the rinse containing che polymer. The treatment was done l/day/5 days per week by applying 5-6 cc. of the rinse on all dentition. The study was double bi.ind. Neither the evaluator nor the people involved in che treatments knew the assignments of rinses in the respective groups. The plaque and gingivitis was assessed via Loe and Silness index (Acta OdontoloRlca Scandinavica. <br><br> .21 :551-555 ( 1963) . <br><br> Results: TABLE III <br><br> Plaque Index/ Gingival Index Mouth Tooth - 4 Wks Z 4 Wks Post % Rinse N Group Post Treatment Change Treatment Change <br><br> Placebo 10 I 0.99 t 0.23 0.91 ± 0.10 <br><br> IX Na2 10 II 0.68 ± 0.23 -31 0.73 ± 0.29 -20 <br><br> VPA Polymer <br><br> Compared to the placebo rinse, the polyvinyl phosphonate rinse significantly reduced plaque/gingivitis for four weeks. <br><br> The following examples of oral (mouthwash and toothpaste) formulations are further illustrative of this Invention. <br><br> EXAMPLE IV Wt. Percent <br><br> Glycor 1 n <br><br> 10.0 <br><br> Ethanol <br><br> 10.0 <br><br> Pluronic F108* <br><br> 3.8 <br><br> Na Saccharin <br><br> 0.0 3 <br><br> Polyvinyl phosphonate <br><br> 1 .0 <br><br> Flavor <br><br> 0.2 2 <br><br> Water to make <br><br> 100.00 <br><br> *BAS F-Wy a ndo 11 e block polymer nonionic surfactant containing alioutj 20 wt.% polyoxypropylcne chain of about 3250 M.W. and about 80wt.Z; polyoxyefhylene . <br><br></p> </div>

Claims (5)

<div class="application article clearfix printTableText" id="claims"> <p lang="en"> 2 10 6 t 3<br><br> EXAMPLE V<br><br> Clycc rin<br><br> Carboxymethy1 Cellulose Sodium Bcnzoate Na Saccharin Silica<br><br> Sodium Lauryl Sulfate Polyvinyl Phosphonate Uater to make<br><br> This invention has been preferred embodiments and it will and variations thereof obvious to be included within the spirit and the scope of the appended claims.<br><br> Wt. Pcrccnt 25.0 1 . 3 0.5 0.2 30.0 1.5 3.0 100.0<br><br> disclosed with respect to be understood that modificatione those skilled in the art are to purview of this application and<br><br> 210018<br><br> WHAT WE CLAIM IS:<br><br>
1. An oral composition for inhibiting human dental plaque and gingivitis by inhibiting attachment of actinomyces viscosus bacteria to tooth surfaces,<br><br> containing a dentally acceptable oral vehicle and an effective plaque-and gingivitis-inhibiting amount of polyvinyl phosphonic acid having a carbon to phosphorus ratio of at least 2:1 and a molecular weight of substantially 6,000 to substantially 8,000, or an orally acceptable salt thereof.<br><br>
2. A composition according to claim 1 containing substantially 0.01% to substantially 10% by weight of the polyvinyl phosphonic acid or salt thereof.<br><br>
3. A composition according to claim 1 containing substantially 0.5% to substantially 5% by weight of the polyvinyl phosphonic acid or salt thereof.<br><br>
4. A composition according to any one of claims 1 to 3 which is a mouthwash having a pH of substantially 4.5 to substantially 9, containing, as a liquid vehicle, aqueous-alcohol.<br><br>
5. A composition according to any one of claims 1 to 3 which is a toothpaste having a pH of substantially 4.5 to substantially 9, containing a liquid vehicle, a gelling agent and a dentally acceptable polishing agent.<br><br> per: AT<br><br> -16-<br><br> west-walker. mccabe, ^<br><br> ,-n.r-vC FOR Ti!E APPLICANT ^<br><br> i0 0 APR 1988<br><br> </p> </div>
NZ210618A 1983-12-28 1984-12-18 Oral composition for inhibiting dental plaque and gingivitis NZ210618A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56636783A 1983-12-28 1983-12-28

Publications (1)

Publication Number Publication Date
NZ210618A true NZ210618A (en) 1988-05-30

Family

ID=24262588

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ210618A NZ210618A (en) 1983-12-28 1984-12-18 Oral composition for inhibiting dental plaque and gingivitis

Country Status (24)

Country Link
JP (1) JPS60169423A (en)
KR (1) KR880002522B1 (en)
AT (1) ATA402284A (en)
AU (1) AU571919B2 (en)
BE (1) BE901404A (en)
CA (1) CA1260837A (en)
CH (1) CH661440A5 (en)
DE (1) DE3445695A1 (en)
DK (1) DK168060B1 (en)
ES (1) ES8800840A1 (en)
FI (1) FI84021C (en)
FR (1) FR2557454B1 (en)
GB (1) GB2151478B (en)
GR (1) GR82565B (en)
HK (1) HK100790A (en)
IT (1) IT1178324B (en)
MX (1) MX171025B (en)
NL (1) NL8403941A (en)
NO (1) NO845265L (en)
NZ (1) NZ210618A (en)
PH (1) PH24564A (en)
PT (1) PT79721A (en)
SE (1) SE502745C2 (en)
SG (1) SG82090G (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877603A (en) * 1987-12-18 1989-10-31 The Procter & Gamble Company Oral compositions
GB2224204B (en) * 1988-10-25 1992-06-03 Colgate Palmolive Co Dental composition comprising polyvinyl phosphonic acid
SE507731C2 (en) * 1988-12-29 1998-07-06 Colgate Palmolive Co Antibacterial oral antiplaque composition
ES2023294A6 (en) * 1988-12-29 1992-01-01 Colgate Palmolive Co Oral compositions anti-plate packaged. (Machine-translation by Google Translate, not legally binding)
IL92693A0 (en) * 1989-08-25 1990-09-17 Colgate Palmolive Co Antibacterial antiplaque composition containing novel styrene-phosphonic acid copolymer
SE512333C2 (en) * 1989-08-25 2000-02-28 Colgate Palmolive Co Antibacterial oral composition with plaque- and tartar-limiting action
ZM5189A1 (en) * 1989-08-25 1990-07-27 Colgate Palmolive Co Antiplaque antibacterial oral composition
US5093170A (en) * 1990-06-25 1992-03-03 The Procter & Gamble Co. Use of a carboxy-substituted polymer to inhibit plaque formation without tooth staining
US5292501A (en) * 1990-06-25 1994-03-08 Degenhardt Charles R Use of a carboxy-substituted polymer to inhibit plaque formation without tooth staining
US5213789A (en) * 1990-08-02 1993-05-25 The Procter & Gamble Company Use of a carboxy-containing copolymer to inhibit plaque formation without tooth staining
EP3100716B1 (en) * 2008-02-08 2018-09-26 Colgate-Palmolive Company Novel salts and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1429963A (en) * 1920-03-01 1922-09-26 George W Nelson Foot-measuring device
US3429963A (en) * 1964-06-09 1969-02-25 Colgate Palmolive Co Dental preparation containing polymeric polyelectrolyte
ZA717486B (en) * 1970-11-19 1973-06-27 Colgate Palmolive Co Treatment of teeth
US4042679A (en) * 1975-11-07 1977-08-16 Colgate-Palmolive Company Antibacterial oral composition
US4138477A (en) * 1976-05-28 1979-02-06 Colgate Palmolive Company Composition to control mouth odor
US4342857A (en) * 1980-12-31 1982-08-03 Colgate-Palmolive Company Antigingivitis composition comprising vinyl phosphonic acid/vinyl phosphonyl fluoride copolymer

Also Published As

Publication number Publication date
DK168060B1 (en) 1994-01-31
NO845265L (en) 1985-07-01
PH24564A (en) 1990-08-03
ES8800840A1 (en) 1987-12-01
AU3717284A (en) 1985-07-04
HK100790A (en) 1990-12-07
SE8406431D0 (en) 1984-12-18
DK617984A (en) 1985-06-29
SG82090G (en) 1990-11-23
ES539087A0 (en) 1987-12-01
KR880002522B1 (en) 1988-11-28
AU571919B2 (en) 1988-04-28
GR82565B (en) 1985-05-07
FI845120L (en) 1985-06-29
NL8403941A (en) 1985-07-16
FI84021C (en) 1991-10-10
IT8449349A0 (en) 1984-12-24
GB2151478A (en) 1985-07-24
MX171025B (en) 1993-09-24
JPS60169423A (en) 1985-09-02
SE502745C2 (en) 1995-12-18
FR2557454A1 (en) 1985-07-05
CA1260837A (en) 1989-09-26
DE3445695A1 (en) 1985-07-11
FI845120A0 (en) 1984-12-27
ATA402284A (en) 1988-11-15
BE901404A (en) 1985-06-28
CH661440A5 (en) 1987-07-31
IT1178324B (en) 1987-09-09
FR2557454B1 (en) 1988-12-16
SE8406431L (en) 1985-06-29
FI84021B (en) 1991-06-28
DK617984D0 (en) 1984-12-20
PT79721A (en) 1985-01-01
GB8432506D0 (en) 1985-02-06
GB2151478B (en) 1987-12-16

Similar Documents

Publication Publication Date Title
US4816245A (en) Antiplaque/antigingivitis method using certain polyphosphonic acids
FI89237B (en) ORAL SAMMANSAETTNING SOM FOERHINDRAR BILDANDE AV TANDSTEN
JP2528492B2 (en) Anti-calculus anti-plaque oral composition
JP2573685B2 (en) Anticalculus oral composition
US4902497A (en) Oral compositions
US4273759A (en) Antibacterial oral composition
US4137303A (en) Antibacterial oral composition
US4272513A (en) Stabilized oral composition
EP0329069B1 (en) Anticalculus oral composition
US4272512A (en) Antigingivitis composition
US4342857A (en) Antigingivitis composition comprising vinyl phosphonic acid/vinyl phosphonyl fluoride copolymer
CA1148088A (en) Dental cream compositions containing a binary fluorine-providing system and dicalcium phosphate
US4309410A (en) Non-staining antigingivitis composition
CA1260837A (en) Antiplaque/antigingivitis composition
JPS61251613A (en) Antiplaque oral composition
EP0311412A2 (en) Anticalculus compositions
US4427652A (en) Antigingivitis composition
GB2224204A (en) Antiplaque/antigingivitis composition
GB1562979A (en) Oral compositions
US20030191209A1 (en) Dental compositions
EP1568356B1 (en) Prevention of dental erosion by use of a colostrum protein
CN113710222A (en) Personal care compositions comprising tetramethylcurcumin and methods of making the compositions
CN113710223A (en) Personal care compositions comprising piperlongumine and methods of making the same